Reflector is Pharm Exec Europe's man inside the EU.
Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.
The Transatlantic Trade and Investment Partnership (TTIP) was the hot tip for a 2014 success story. But as summer slides away, the latest read-out of progress suggests that rather than remaining a hot tip, TTIP is now risking oblivion...
Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.
Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.
Rare allies—innovator and generic pharmas—are calling for policy integration in Europe. But ideology and newfound scepticism on the merits of drugs in healthcare could complicate the effort.
Because of the tougher conditions they face and shifts in ownership and corporate strategy, EFPIA and EGA have started to work together much more closely.
Politicians and health campaigners are celebrating the final agreement of the EU's new clinical trials rules. But the European drug industry is not so euphoric, writes Reflector.
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Roche and Novartis have been fined in Italy on pricing conspiracy charges, fueling a wider debate in Europe about expenditure, efficiency and off-label prescribing.
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
Sponsored By Oracle
Multi-faceted Approaches to Meet Payer and Regulatory Evidence Requirements
Sponsored By UBC Express Scripts
Overcoming the Life Sciences Content Conundrum in a Multichannel World
Sponsored By Veeva